Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022

All proposed resolutions approved All existing members re-appointed Board strengthened and diversified HALLE (SAALE) / MUNICH, GERMANY, June 22, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: […]

Vivoryon Therapeutics Announces Update on Phase 2b Alzheimer’s Clinical Trial, VIVIAD

Vivoryon has extended the trial protocol through the inclusion of exploratory parameters and plans to enroll patients in selected study sites in Denmark, Germany and the […]